Well, us our today. good We afternoon, thank for call you having you, Deb, appreciate and join everyone.
million on quarter, $XXX our start quarter Let's of per reported for share to $X.XX adjusted X. led and share. million revenue results fourth we Today, $XXX our with adjusted of in the Slide EBITDA earnings per
the $XX fourth revenue multiple business RNA continued of vaccine infectious across marks and XX% messenger million XXXX, quarter uptake of immuno-oncology therapeutic a quarter, demonstrating over technologies base platform Our of revenue widespread record up programs. disease the
the end provided per share share for put of per our quarter's quarter for us call. during of earnings last $X.XX year range EPS and adjusted $X.XX Our guidance the full top at the
adjusted was was As with an for revenue was margins entire XX%. indicates, million Slide XXXX coming business. record $XXX at $XXX and Full million, income EBITDA in year incredible a net the X year
XXXX divestiture for of business full business importantly, grew XX%. revenue our year XXXX when detection base our protein the adjusted Most
CleanCap be deliver accelerating services our reason offer core to XX% from to gene enable we to the that therapy cell excluding exact We continues advanced continue this sales related market the Kevin The base business, and the as and around business base products will services. You COVID to well. is at hearing shortly technologies this year expect our demand a that that just on development. for moment. simply manufacturing and in grow More
X. Slide Turning to now
revenue remaining of quarter of includes over million Our revenue. CleanCap Nucleic quarter. The had base business, revenue COVID fourth the Acid Production $XX in for largest $XXX estimated of $XXX million last year. base XXX% business million This up quarter an NAP ever of the our four represents
Production Nucleic $XXX NAP the For growing Acid at was XXXX $XXX XX%. the full revenue revenue year, over base with XX% growing million, total million,
last encouraged for CleanCap very business GMP base and our and reagents see constructs. year's manufacturing are continue both RNA and We mRNA growth to services by strong demand messenger
modified RNA reactions. vitro nucleotide providing triphosphate unique opportunity improve base raw materials including our newest critical CleanCap to across and GMP-grade have and customer messenger in a early-stage our We while transcription technologies inclusion drive nucleoside to
for through and commercial leadership our look Buzzeo’s is these beyond. services Maravai’s the with customers for gene the support programs greater to XXXX unique early-stage in mRNA Our strategy commercialization. and and process, as continue their to right The needs under is programs products during to and ever Becky win development clinical to than discovery of we cell therapy need
and over FDA such that for investigational X,XXX cystic behind or X. now alone patients Slide to of recently cell drug They cell active X,XXX fibrosis. as and diverse there and also progressing Alliance cell applications indicated to gene levels. in Let's CGT The therapies than rapidly The move billion Regenerative IND line is with across new anticipate of the gene challenges new immense science now saw According greater and benefit gene health cancer therapies report, is IND XXXX. Medicine pre-pandemic investment XXX starts clinical XXXX, in the applications the $XX active therapy trial space therapies. industry latest for and over for their in to are which
cell. dNTP supply of incredibly plasmid profile now delivered cell is gene manufacturing CleanCap donor, this RNA In key of that cells. since DNA cell most genetically facilitate manufacture patient introduce, used change mRNA transcript acid required cell modified either the engineer process. critical them used the into positive effective a remove more This to a messenger modified making market. targeting materials or or therapies, of patient-specific and a often molecules. actually or biologically nucleic for Maravai In many the at this effective news To we particular cells the ensure are DNA raw the the enzymes material for cancer genetic therapy, RNA type select of growing from case In considered reagents or transfer to in raw the therapy, directly and is the production supply rapidly is or RNA to mRNA of
of the for leader CleanCap and the RNA the for manufacture necessary mRNA transcripts. a production case a Maravai best-in-class and is GMP top gene As world therapy, dNTPs reagents, in is messenger of supplier including
there at of levels. guide critical successful faulty RNA The gene applications are expedite correct where new very diseases GMP In to of is both often next Biologics or the work stranded through the pilot the possible Center manufacturers therapies. messenger genome DNA also Cas rare and remove Research is combination or disrupt to at of expresses refer RNA key that and as of the the We're these replaced Maravai approval that the what or operation process supplies quality nuclease. interest. plans specifically idea for currently inserted, editing for as as components to CBER in a encouraged Evaluation aimed and FDA's speed diseases.” to within therapeutics sequences gene novel is of DNA gene, the here “The the modified available no move cell The they is rapidly directly rare regulatory goal of drug to editing, deleted, to generation
you messenger imagine, might RNA upon may and therapies. cell gene well programs or other these of be many As based
Turning now to Slide X.
from third-party share an with to commissioned analysis we me our you a update specific Let CleanCap programs.
trials recently may refresh and have recall A you identified CleanCap in and You containing more now that of conditions. preclinical different is told These Phase increase. a that that programs our a messenger human or identified work over period. XXX earnings May, That call than XXX using we short programs programs for XX-month variety XX health we programs in that XX% RNA. preclinical use through we've was III a completed of CleanCap in new include clinical
identified our those programs applications. here or services. our direct these almost the shows half RNA followed in we is phase many include the products out you heat programs view programs About Now are right-hand of target for what X messenger to is of be the and and diseases. top which the And spot cancer, of X side vaccines of as the preclinical current of sweet disease closely therapeutic infectious map on by
chart applications, and in mRNA And vaccines, in the product slide multiple innovators you see and here the as our will RNA for products This what part customer for a this the seen continuous middle that or of including sizes development. interest can pipeline share sustained in earliest stages believe disease cancer pipeline keep infectious in the market new this or platform the modalities, of other the contours Growth of the to very ring across come multiple innovation and biopharma through in of at of commercial vaccines of is a lower technologies investments share widespread first we industry. gain messenger reflects pharma position are services. to cell in and foreshadows Therefore, all We therapies their field. large we RNA. in unique the because the future reflects big be future were messenger of wallet programs use able in market of one mind us that both number and truly our
is the from quite today, are we future good there's looks numbers bands. X sharing and of favorite certainly can you Timbuk that one As a reason that see bright, my
XX pleased developments enzyme acquired production. a know let turn to specialty you in that have let's exciting and Alphazyme, I'm Slide further some Maravai. to leader for we Now
Acid of most messenger you are across a The further addition of production successfully collaborating marrow's As Nucleic This undoubtedly these manufacturers customers solutions. product Alphazyme's us know, range their process optimizing products. will acid be of RNA products Production. history enzymes position more platforms of expertise enzyme position complete and detection almost to development and of in therapies and portfolio with allows every customers History to strengthen critical capabilities even phase and to to of choice relationship processes. first offer our nucleic Maravai their production and our unique and complementary lighter with adds
and Alphazyme's will Additionally, knowledge deep intellectual extend our own enzyme innovation process property capabilities.
of has its with past composed the of a enzymes well-experienced and key messenger cutting-edge and oligonucleotide Alphazyme synthesis. for Alphazyme’s And our we strong enzymes complement provide mRNA customer critical experience proprietary to for solidifies core provide Chris acquisitions, science. RNA They is therapeutics. focused a been one-stop by is team expertise. methods a chemistry inputs as led Co-Founders, As custom our our technical case Chad developing for Decker believe shop and Benoit this on acquisition
and exceptionally talented innovation. team Chris to welcome manufacturing drive to pleased process are Chad's tomorrow We our and help
Now Slide and business. XX to turning Testing Safety Biologics our
you our therapy, biologics support As products cell markets know, drug and of gene vaccines in BST and and the manufacturing. services
solutions our the safety customers with impurity biopharmaceutical set products. we global protein their prediction and in ensure clearance along analytics, help wholesale gold standard that the process-related offering viral of innovative Here,
about Our revenue BST fourth down year. $XX in million from X% of last quarter was
X% For million just the revenue of levels. from grew our XXXX $XX BST over year, full
have we roughly initial affected a negatively COVID million as year As war. the Zero negative in been China discussed, the Russia-Ukraine as business BST this by impact has $X from well previously policies the
fourth persisted in widely coded China. Some of that quarter spread across as the weakness
a and and cancer. infectious manufacture and proteins recombinant vaccines, segment including this of biopharmaceutical broad novel in disease to include biosimilars customers as monoclonal Our These prevent and biologics recombinant products. both vaccines antibodies treatment range
in provide of also gene of the cells. and products development cell therapies We in support
Slide produced various produced to on and Recombinant technologies. leachate, detail our culturing require therapy cell enzymes. acid gene share BST therapies cell of vaccines using cell presence and residual on including the very some lines, of requirement, CAR-T vectors rely growth to used vector pleased be T cell the Cygnus and proteins, XXXX. as I'm host-cell for cellular Turning gene I'd host XX gene HCP in and CAR and market. process-related a analytics, manufacture viral cell gene XX. further DNA, the Viral media host approved as tested component of such known like purified host as vectors recombinant viral impurities approved testing XX these cell the therapies the manufacturing for proteins. in EMA and for Per therapies therapies then growing or product out of rigorous certain cell regulatory tests must nucleic additives XX kits that processes and for traction of FDA purification lot and commercial therapies protein during ELISA use X release. were cell
catalog services plan to for BST most customers' and superior ensure highest business our meet the to scale our BST priority Nucleic of simply the quality very feels a comprehensive remains the products offerings Maravai. size to products to to often and and offer While somewhat technical scale long-term business, and overshadowed We our growth needs. due opportunity the a Production attractive support key Acid of
in our here. Leland, and us Carolina to facility innovate continue new will Our support expand North to analytical allow
Slide to organizational moving updates. XX some Now and
will Biologics Testing. to report and our in revenue two Acid We Nucleic Production segments, Safety continue reporting
to now our evolved serve. internal organization have we we support and different customers However, markets
us internal follows. provide as Alphazyme, and new Our and aligned enable a sustainable our in have growth. experience us position the to with we differentiated acquisition will help Beginning structure customer for XXXX better of businesses
the acid these organized production, three we units. clinic around are Within
team. with Nucleic our from nucleic The ensure team the focused product The and shared to on we complementary cell broader drug Glen to adds our be first products. and an acid therapy The in focused are TriLink. acid our services with Nucleic is of the standalone third of the needs new Production teams meeting acid market gene own expertise Alphazyme manufacturing customers production solutions extension nucleic and on Their and development a well building their an integrated enzyme both organization. positioned customers is which to of provides products And is services. is chemistry products and and development development is that group portfolio capabilities Acid team partnerships customers. serve enzymes, specific custom the range of as for
molecular test. innovators medicines support to to for biology Alphazyme and RNA develop enzymes genetic will DNA genomic continue and produce and molecules,
up are now So that groups for segment us. make three the the NAP these
our and Christine Testing Dolan regulatory including development. needs Trey biotherapeutics, supports comprised Biologics Officer. team the developing and by detection producing analytical Cygnus and of is improved segment bioprocess of solutions is and Safety as led Our that Martin Operating President; quality Chief This team customers as and
also know by we of Dr. I'm a that to pleased Innovation let Office Science led and launched have you Kate Broderick. new
joined R&D lead efforts. Nucleic You year Kate Production to recall, last us may our Acid
value new drive leadership ensure We establish have strategy Chief She and and that to tasked our scientific with as will footprint. new roadmap position. she her In with and partner processes expanded execute her innovation overarching an development Maravai the and expand R&D, and will scientific and technological develop for our Officer, are and our technology role, responsibilities closely Innovation the customers. Maravai this culture Kate driving for innovations, throughout team report maintains
repurposed new of partner to to their leverage At order Maravai these have optimize us in with support to to scale. each offices level, closely and will be center growth, the the efforts. organization services for MyChem and R&D processes in We resources Diego San here continue to support our excellence shared a
Slide now Turning to XX.
long-term our ESG advancements safety Along the A growth, we how forward with from core the soon-to-be to are second published will in positioning look cover governance on for with we path that and be will March. goes The pleased infrastructure environmental proud step meticulously governance and the consciousness of our Our ourselves and environmental, achieving examples be ESG to towards XXXX. and strategic greater expansive question, our the first report with honest before transparency report results. growth. program sustainable necessary our our I year and that sustainable ESG will fiscal disclosure increased objectives. quality Without our are business hand data. report an the our build of is we social and commitment let founded intrinsic in have to tangible our strategy company's since Environmental date been to and of highlights sharing and to to of of you progress XXXX Eric end improve know and stewardship, transparency in provide effective are Maravai focused published working and and hand into products, values our our few include social I'm
signed usage by We XXXX to our for equity calculating X, gas facilities first each Scope have foster completed and I Pledge measuring X ensure that of in advance proper programs, our our to and taking To footprint greenhouse exercise and and and Diversity Scope and environmental commitment demonstrate place emissions DI at last waste Inclusion to and XXXX. for Action inclusive the the we and our our water diversity, training have action CEO been a culture. summer, more inclusion, resources we
difficulty] leadership For [technical with our group, first launched resource employee example, in women we
and a an parity onboarding leadership an XXXX, I to enhanced a XX% orientation by to am of is executive In process our very XX growth more many introduction training new have and employee that organization, implementing also proud gender including as new program leadership for comprehensive facets all women. improved our is hires. and to believe of We than the business provide team our hours we necessary for
for new a path adopted growth also committee improve updated our respective Board Our their sustainable structure charters to oversight and forward. on
and committed forward to corporate We a on keeping strong are apprised our you being to citizen look journey.
Slide to XX. turning Now
over $XXX growth COVID-XX at of business introducing revenue that our release press we million revenue to the This for CleanCap our million. assumption guidance GAAP XX% $XXX of includes base and rate million the from of XXXX $XXX midpoint. saw an are the You
viruses XXXX product the the customer that of foundational revenue ongoing from or anticipate vaccine approaches. multiple peak future. COVID we expect for for demand, While revenue support was flexibility stand-alone respiratory include the CleanCap could vaccines, given contributions This respiratory year CleanCap both demand foreseeable CleanCap our do coved combination to we multiple
updated primary shot met vaccination COVID-XX As on the FDA BA.X/X-bivalent the recommended vaccines XX, use it simplify vaccine both final note here, moves strategy. for country's the advisory as of and latest a to the January booster and unanimously panel
and were plans around a what for that straining broadly move programs experts U.S. similar the and autumn/winter composition and future booster about with the Additionally, periodically for supported. data review seasonal updates happens COVID annual to COVID discussed any propose to believe strains flu circulating vaccines, composition the to vaccine is will world We vaccine the where campaign, of selection newly can to Meanwhile, vaccines offering and innovate gather virus which updated approximately be that narrow a manufacturers create virus. between continue durable days. of specified or of to coverage transmission can prevent that to variant the health vaccine necessary. officials mRNA may more are the XXX strain vaccines, further better delivery is advantage here The window vaccine public improved
of in involved many are development We these programs.
cover fourth Kevin? our year on ask now with our guidance full I'll quarter our performance, assumptions. along details more Kevin model and and to
